Connor Iapoce

Our Cardiology Month in Review for November 2024 spotlights the approval of acoramidis and top content from AHA 2024.

Insufficient ferric carboxymaltose dosing and timing fail to significantly improve hemoglobin levels, suggesting gaps in perioperative anemia management.

ONS-5010 missed the pre-specified non-inferiority endpoint set with the FDA, but Outlook Therapeutics plans to resubmit the BLA in Q1 of 2025.

David G. Armstrong, DPM, PhD, and Michael S. Conte, MD discuss Phase 2 results on anatomically directed lower extremity gene therapy for ulcer healing.

Amgen’s MariTide achieved up to 20% average weight loss at 52 weeks without hitting a plateau in individuals with obesity or overweight.

The FDA set the Prescription Drug User Fee Act (PDUFA) date for the investigational RNAi therapeutic as March 23, 2025.

New 52-week LUNA and 4-year OPTIC data demonstrate Ixo-vec’s potential to reduce injection burden, maintain vision, and achieve lifelong benefits for wet AMD.

FDA grants Rare Pediatric Disease, Fast Track designations to gildeuretinol, aiming to accelerate treatment for Stargardt disease.

The sNDA was intended to include positive two-year data in the US Prescribing Information for avacincaptad pegol based on the GATHER2 clinical trial.

Birgit Vogel, MD discusses racial inequities and geographic variations in peripheral artery disease care in the United States.

Milind Desai, MD describes favorable real-world safety outcomes from mavacamten use over 22 months of the Risk Evaluation and Mitigation Strategy (REMS) program.

Marianna Fontana, MD, PhD discusses Phase 1 interim results on the CRISPR-based gene-editing therapy, nex-z, for ATTR-CM.

Stephen J. Nicholls, MD, PhD discusses the robust efficacy and tolerability of zerlasiran for Lp(a) lowering, paving the way for Phase 3 development.

Marianna Fontana, MD, PhD describes the prognostic importance of a decline in eGFR in a retrospective cohort of patients with ATTR-CM.

A nasal spray form of bumetanide reduced tissue swelling from heart failure as effectively as the oral and intravenous formulations.

Sacubitril/valsartan reduced the risk of heart damage among high-risk cancer patients treated with anthracycline chemotherapy agents.

Christian. T. Ruff, MD, MPH describes an analysis of AZALEA-TIMI 71 demonstrating the substantial benefit of abelacimab on bleeding outcomes in patients on antiplatelet therapy.

Barry A. Borlaug, MD describes the beneficial effect of tirzepatide on circulatory pressure-volume overload and end-organ damage in patients with HFpEF and obesity.

An IV infusion of exenatide during cardiac surgeries involving bypass did not significantly benefit mortality or organ injury compared with placebo.

A single dose of nex-z achieved consistent and rapid reductions in serum TTR levels over 12 months of follow-up in patients with ATTR-CM.

Initial catheter ablation achieved a lower risk of a composite primary endpoint event than anti-arrhythmic drug therapy in patients who survived a heart attack.

Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with diabetes in the BPROAD trial.

Once-daily aprocitentan is indicated to help lower blood pressure in adult patients with hypertension who are inadequately controlled on other medications.

A 6-year longitudinal study, involving more than 200,000 adults, reported a notable rise in dyslipidemia incidence during the COVID-19 pandemic.

The VARIPULSE platform enables AF treatment with a single device combining pulsed field ablation therapy and mapping with the CARTO 3 system.

Work-related stress associated with adverse cardiovascular health in diverse US adult population, indicating potential risk factor for CVD prevention.

Survey data show pharmacists are integral to HCV screening and treatment across healthcare settings, highlighting their contributions to HCV elimination efforts.

Alcohol relapses were detected more frequently after the introduction of phosphatidylethanol in orthotopic liver transplant recipients.

According to Phase 3 LIBERTY-CUPID trial results, dupilumab significantly reduces itch and hive activity from baseline in chronic spontaneous urticaria.

Risankizumab achieves significantly higher rates of skin clearance and improved quality of life versus deucravacitinib in matching-adjusted indirect comparison analysis.